JP2023505756A - EphA2に特異的な二環式ペプチドリガンドおよびその使用 - Google Patents

EphA2に特異的な二環式ペプチドリガンドおよびその使用 Download PDF

Info

Publication number
JP2023505756A
JP2023505756A JP2022531404A JP2022531404A JP2023505756A JP 2023505756 A JP2023505756 A JP 2023505756A JP 2022531404 A JP2022531404 A JP 2022531404A JP 2022531404 A JP2022531404 A JP 2022531404A JP 2023505756 A JP2023505756 A JP 2023505756A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
solution
formulation
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022531404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505756A5 (enExample
Inventor
ベネット,ギャビン
マーンケ,リサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2023505756A publication Critical patent/JP2023505756A/ja
Publication of JP2023505756A5 publication Critical patent/JP2023505756A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022531404A 2019-11-27 2020-11-27 EphA2に特異的な二環式ペプチドリガンドおよびその使用 Pending JP2023505756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962940966P 2019-11-27 2019-11-27
US62/940,966 2019-11-27
PCT/GB2020/053026 WO2021105694A1 (en) 2019-11-27 2020-11-27 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2023505756A true JP2023505756A (ja) 2023-02-13
JP2023505756A5 JP2023505756A5 (enExample) 2023-12-05

Family

ID=73854820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022531404A Pending JP2023505756A (ja) 2019-11-27 2020-11-27 EphA2に特異的な二環式ペプチドリガンドおよびその使用

Country Status (10)

Country Link
US (1) US20230025916A1 (enExample)
EP (1) EP4065085A1 (enExample)
JP (1) JP2023505756A (enExample)
KR (1) KR20220131898A (enExample)
CN (1) CN114760988A (enExample)
AU (1) AU2020392890B2 (enExample)
CA (1) CA3158741A1 (enExample)
IL (1) IL293200A (enExample)
MX (1) MX2022006001A (enExample)
WO (1) WO2021105694A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
CA3095582A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4165414A1 (en) * 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
EP4382130A4 (en) * 2021-08-17 2025-12-24 Tianjin Conjustar Biologics Co Ltd Conjugated polypeptide-drug with a novel structure and its application
EP4719480A1 (en) * 2023-06-01 2026-04-08 BicycleTx Limited Bicyclic peptide ligands specific for epha2 and uses thereof
WO2024248860A1 (en) * 2023-06-01 2024-12-05 Bicycletx Limited Bicyclic peptide ligands specific for epha2 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190184025A1 (en) * 2017-12-19 2019-06-20 Bicycletx Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190184025A1 (en) * 2017-12-19 2019-06-20 Bicycletx Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. vol. 78, suppl 13, JPN6024042413, 2018, pages 5854, ISSN: 0005442739 *
SCI REP, vol. vol. 9(1), JPN6024042412, 22 February 2019 (2019-02-22), pages 2636 - 1, ISSN: 0005442740 *

Also Published As

Publication number Publication date
MX2022006001A (es) 2022-10-27
IL293200A (en) 2022-07-01
CA3158741A1 (en) 2021-06-03
AU2020392890A1 (en) 2022-06-02
US20230025916A1 (en) 2023-01-26
EP4065085A1 (en) 2022-10-05
WO2021105694A1 (en) 2021-06-03
CN114760988A (zh) 2022-07-15
KR20220131898A (ko) 2022-09-29
AU2020392890B2 (en) 2026-06-25

Similar Documents

Publication Publication Date Title
KR20220131898A (ko) EphA2에 특이적인 바이사이클릭 펩티드 리간드 및 이의 용도
JP2023526451A (ja) ネクチン-4に特異的な二環式ペプチドリガンド及びその使用
JP2024545125A (ja) Stat3分解剤およびその使用
KR20240100420A (ko) 암을 치료하기 위한 방법
EP4719480A1 (en) Bicyclic peptide ligands specific for epha2 and uses thereof
EP4719481A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2024248859A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
JP7282045B2 (ja) B型肝炎ウイルス感染を特徴とする肝細胞癌の治療
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
EP1945182B1 (en) Formulations of tipifarnib for intravenous application
EA046145B1 (ru) Фармацевтические композиции, содержащие конъюгат, содержащий токсин и бициклический пептид, и способы их применения
AU2023449926A1 (en) Bicyclic peptide ligands specific for epha2 and uses thereof
WO2025056907A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
EA047123B1 (ru) Бициклические пептидные лиганды, специфические для нектина-4, и их применение
WO2025125809A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
CN118450891A (zh) Stat3降解物及其用途
WO2025125648A1 (en) Bicyclic peptide complex for use in treating cancer
EA043796B1 (ru) Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250805